Introduction
Small cell lung cancer (SCLC) is a high-grade neuroendocrine carcinoma that accounts for 15% of lung cancer cases [
1]. It is often diagnosed at a late stage with two-thirds of patients having distant metastasis at initial diagnosis [
1]. Extensive-stage SCLC (ES-SCLC), which refers to disease beyond one hemithorax and one radiation port, has a particularly poor prognosis with a 30-month survival rate of less than 10% [
1]. Chemotherapy has been the mainstay of the treatment for ES-SCLC. Recently, immuno-oncology (IO) agents were shown to improve survival when used in combination with chemotherapy, which led to the approval of atezolizumab and durvalumab for first-line treatment of ES-SCLC [
2‐
4]. Despite these new treatments, the majority of patients experience relapse within 6 months [
2]. The treatments for relapsed ES-SCLC are even more limited with suboptimal efficacy [
5]. Topotecan was the only treatment approved for second-line ES-SCLC in the USA until June 2020 [
2,
5]. Currently, the National Comprehensive Cancer Network (NCCN) guidelines recommend etoposide and carboplatin (EP) with and without an IO agent (atezolizumab or durvalumab) as first-line therapy and regimens containing topotecan or lurbinectedin as second-line therapy [
6,
7].
Chemotherapy is known for associated myelosuppressive adverse events, resulting from direct damage to hematopoietic stem and progenitor cells (HSPCs) in the bone marrow or an indirect effect, such as reduced production of erythropoietin [
8]. Chemotherapy-induced myelosuppression (CIM) occurs because chemotherapy drugs not only target tumor cells but also normal HSPCs, both of which are in constant proliferation. It affects multiple lineages and often presents as neutropenia, anemia, and thrombocytopenia [
8‐
11], which are the most common treatment-related adverse events reported for patients with SCLC in real-world studies [
12]. Despite overall effort of improving cancer management, incidence of CIM in patients with SCLC remained consistent between 2012 and 2015 [
13]. More recently, a study reported that over 55% of patients with ES-SCLC experienced grade ≥ 3 myelosuppressive hematologic adverse events (HAEs) after receiving chemotherapy in community practices, including approximately one-third with grade ≥ 3 myelosuppressive HAEs in two or more lineages [
14]. Clinically, CIM is associated with an increased risk of infection, bleeding, and mortality [
8,
10,
11]. Severe CIM often leads to dose reduction, treatment delay, or discontinuation [
14‐
16], which may compromise treatment outcomes in patients with cancer, such as disease control and survival [
15,
17,
18]. In addition, symptoms associated with the myelosuppressive HAEs can substantially reduce patients’ quality of life (QoL) [
19]. Therefore, CIM management is an important part of treatment of ES-SCLC. Treatment for CIM mainly consists of supportive care, e.g., granulocyte colony-stimulating factors (G-CSFs) for neutropenia and erythropoiesis-stimulating agents (ESAs) for anemia [
9,
10]. For patients with severe myelosuppressive HAEs, red blood cell (RBC) or platelet transfusion and hospitalization may be required [
6,
9,
11]. Treatments for CIM and its associated complications pose substantial economic burden to healthcare systems. In the USA, annual incremental costs associated with grade ≥ 3 myelosuppressive HAEs among patients with SCLC ranged from $22,251 for thrombocytopenia to $63,245 for neutropenia [
20]. Moreover, healthcare resource utilization (HCRU) increased with the number of lineages involved [
21]. The above evidence suggests that there remains substantial unmet need for new therapies that can effectively manage CIM in patients with ES-SCLC, improve patients’ QoL, and reduce the economic burden borne by patients and healthcare systems.
Trilaciclib is the first and only therapy that helps proactively protect HSPCs, the source of all blood cell lineages [
5]. Trilaciclib transiently arrests HSPC in the G1 phase of the cell cycle by inhibiting the activity of cyclin-dependent kinases (CDK) 4/6, an important factor in the process of the proliferation of HSPCs [
22]. Trilaciclib, as an innovative transient CDK4/6 inhibitor, when used before the start of chemotherapy, can prevent HSPCs from proliferating in the presence of cytotoxic chemotherapy, thereby protecting multiple cell lineages from cytotoxic effects of chemotherapy [
22]. In three randomized phase 2 clinical trials and the pooled analyses of these trials [
23‐
28], trilaciclib has been shown to effectively reduce myelosuppression in multiple lineages and decrease cytopenia-related healthcare utilization. These effects have been demonstrated when trilaciclib was administered prior to EP or EP plus atezolizumab in the first-line setting and prior to topotecan-containing regimens in previously treated ES-SCLC. On the basis of these results, the US Food and Drug Administration (FDA) approved trilaciclib for decreasing the incidence of CIM among adults with ES-SCLC when administered prior to EP- or topotecan-containing regimens in February 2021 [
29]. The NCCN guidelines also recommend trilaciclib as a prophylactic treatment to reduce the incidence of CIM in ES-SCLC [
6,
7]. In addition to its clinical efficacy, trilaciclib has also been shown to reduce the overall healthcare costs and improve quality-adjusted life years among patients with ES-SCLC [
30‐
32].
To date, there is limited evidence on the real-world outcomes associated with trilaciclib use in ES-SCLC. The patient populations and treatment outcomes in real-world settings may be different from those observed in clinical trials. To enhance our understanding of the real-world outcomes of trilaciclib, the current study was conducted to comprehensively review the current literature and synthesize the effectiveness of trilaciclib in real-world settings. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
Methods
Literature Review Approach
A comprehensive literature search of the MEDLINE, Embase, and Northern Light Life Sciences Conference Abstract databases was performed on November 28, 2022, using the following keyword combinations: (“small-cell lung cancer” or “SCLC”) and (“trilaciclib” or “Cosela”). To be included in the review, a study must have met the following inclusion criteria: (1) focused on the ES-SCLC population; (2) included patients receiving trilaciclib; (3) included one of the key outcomes of interest related to CIM, such as myelosuppressive HAEs or cytopenia-related resource utilization; (4) was a real-world observational study; and (5) was published in English. The review included full-text articles published from the inception of MEDLINE or Embase to the search date and conference abstracts from 3 years prior to the search date. Clinical trials, narrative reviews, and any type of publication other than original research were excluded. In addition, a search was conducted by hand to identify relevant reviews and studies not included in the electronic databases. As trilaciclib is a relatively new drug, the co-authors of the relevant studies provided additional data that were unpublished (but accepted for future publication or presentation) as of the search date. Moreover, additional unpublished data on file for the published or presented studies was solicited from the authors to enhance our understanding of these studies.
Following the Centre for Review and Dissemination (CRD) guidance [
33], two levels of screening were performed. Level 1 screened titles and abstracts identified from the literature search and level 2 screened full-text articles identified as possibly relevant studies from the level 1 screening. Each level of screening was performed by two independent reviewers and discrepancies were resolved by a third reviewer. After eligible studies were identified, data extraction was conducted to extract information on study design, data source, baseline characteristics, and outcomes of interest from each included study.
To facilitate the interpretation of the real-world outcomes of trilaciclib-treated patients with ES-SCLC, the study also strived to identify comparable non-trilaciclib studies that evaluated similar outcomes among patients with ES-SCLC who did not receive trilaciclib from the same data sources. Similar data extraction was performed for each of the identified non-trilaciclib studies.
Outcomes of Interest
The main outcomes of interest for this review were myelosuppressive HAEs and cytopenia-related healthcare utilization. Specifically, myelosuppressive HAEs included any grade ≥ 3 anemia, neutropenia, and thrombocytopenia, as confirmed by laboratory tests. The study included outcomes for a single lineage (overall and by grade) as well as multiple lineages (i.e., two or three lineages). Cytopenia-related healthcare utilization included G-CSF, ESAs, RBC and platelet transfusions, and intravenous (IV) hydration. G-CSF use was evaluated within the first 3 days following the index date and during the defined outcome observation period (Table
1), with the former used as a proxy measure for prophylactic G-CSF use. Other outcomes (e.g., hospitalizations, dose reduction, and treatment delay) reported in eligible studies were also extracted and summarized.
Table 1
Study design of real-world trilaciclib studies and historical non-trilaciclib studies
Data source | | iKnowMed EHR structured data from the US Oncology Network | iKnowMed EHR structured data from non-network community oncology practices | Florida Cancer Specialists & Research Institute structured EMR database | The Integra Connect Structured & Curated EMR and Claims database |
Geographic location | | USA | USA | Florida | USA |
Patient identification period | Trilaciclib | Feb 2021–Apr 2022 | Feb 2021–May 2022 | Jan 2017–Dec 2021 |
Non-trilaciclib | Jan 2015–Dec 2019 | Sep 2013–Nov 2020 | Jan 2015–Mar 2021 |
Index date | Trilaciclib | Date of trilaciclib initiation with LOT1 or LOT2+ | Date of chemotherapy initiation when trilaciclib was used in the initial chemotherapy regimen |
Non-trilaciclib | Date of chemotherapy initiation |
Time horizon for outcome observation for myelosuppressive HAEs, cytopenia-related healthcare utilization, and dose reduction and treatment delay | Trilaciclib | From index date to 14 days after last trilaciclib administration of index chemotherapy regimen | During chemotherapy cycles when trilaciclib was used | From index date to end of follow-upa |
Non-trilaciclib | From index date to end of follow-upa |
Outcome measuresb |
Grade ≥ 3 myelosuppressive HAEsc | | Grade ≥ 3 myelosuppressive HAEs were identified using laboratory values based on CTCAE v5.0 definitions All studies reported the myelosuppressive HAE rates by lineage and grade |
Cytopenia-related healthcare utilization | | Included G-CSF and ESAs |
RBC or platelet transfusion | | Based on lab proxy, i.e., hemoglobin < 8 g/dL; platelets < 10,000/µL | Transfusions occurred |
Dose reduction and dose delay | | Dose reduction was defined as a decrease in dosage compared to the baseline or previous dose. A dose reduction of at least one drug was counted as an event for dose reduction Dose delay was defined as a gap of less than 60 days without treatment | Not available | Not available |
Hospitalization | | Not available | Not available | Hospitalization rates between day 8 and 16 and between day 1 and 21 LOS |
IV hydration | | IV hydration was determined on the basis of the structured EHR, if captured in the database | Not available |
Subgroup analysis of trilaciclib | LOT1 trilaciclib initiators | Defined as initiation of trilaciclib before LOT1 cycle 1 | Defined as initiation of trilaciclib at LOT1 | Not available |
Evidence Synthesis
Identified eligible trilaciclib studies were first synthesized qualitatively. Specifically, key study design elements, including study year, sample selection criteria, sample size, index date, and follow-up period were summarized for each study, along with their similarities and differences. Baseline characteristics were summarized and compared qualitatively across studies. Definitions of the outcomes of interest were evaluated, and if they were similar, a quantitative synthesis was conducted by estimating weighted averages of the outcomes using sample size as the weight. The analysis was conducted separately for the trilaciclib and historical non-trilaciclib cohorts. Depending on availability, treatment outcomes were further compared qualitatively between trilaciclib- and non-trilaciclib-treated patients (i.e., directionality) on the basis of the results from individual studies and the quantitative synthesis. In addition, results for subgroups of trilaciclib-treated patients (who initiated trilaciclib before or during first line of therapy [LOT1]) were also summarized, if available.
Discussion
Trilaciclib is the first treatment in its class approved by the FDA for decreasing the incidence of CIM in adult patients with ES-SCLC who received platinum/etoposide-containing or topotecan-containing chemotherapies. It proactively protects HSPCs and thus impacts all lineages. As ES-SCLC mainly affects elderly patients who are at an increased risk of CIM and reduced dose intensity [
15], trilaciclib may potentially improve the treatment outcomes of chemotherapy in this population. To date, most of the evidence on trilaciclib effectiveness was based on clinical trials. However, real-world outcomes constitute an important part of treatment decision-making because clinical trial results may not be reflected in real-world practice wherein trilaciclib-treated patients are more heterogenous and have some distinctive features compared to the clinical trial population. For example, they appeared to be older (49–81% were age 65 or older in real-world studies, compared to 46% in the pooled results from the three clinical trials) and have fewer male patients (44–52% in real-world studies, compared to 72% in pooled results from the three clinical trials) [
26]. On the basis of the available data, real-world trilaciclib-treated patients appeared to have poorer performance status based on the ECOG score of 0/1 (82.6–85.7% in real-world studies vs. overall 87.8% among the clinical trials). Furthermore, trilaciclib was initiated before cycle 1 of chemotherapy in the clinical trials, whereas trilaciclib can be initiated after cycle 1 of chemotherapy in the real world as a result of various reasons. Therefore, it is important to confirm the clinical trial findings in real-world settings. To our knowledge, the current study is the first one to comprehensively review the literature and synthesize the real-world outcomes of trilaciclib in ES-SCLC.
The real-world evidence on trilaciclib is limited, primarily as a result of its recent approval. However, the existing evidence supports the real-world effectiveness of trilaciclib in ES-SCLC. The synthesized evidence showed that trilaciclib-treated patients had numerically lower prevalence of grade ≥ 3 myelosuppressive HAE in at least one lineage, grade ≥ 3 myelosuppressive HAE in each lineage (i.e., neutropenia, anemia, and thrombocytopenia), and multilineage grade ≥ 3 myelosuppressive HAEs in reference to the outcomes of non-trilaciclib-treated patients from the same databases (i.e., historical comparisons). In particular, the differences were more prominent in grade 4 compared to grade 3 myelosuppressive HAEs, suggesting that trilaciclib may not only reduce the prevalence of grade ≥ 3 myelosuppressive HAEs but also the severity of myelosuppressive HAEs. Of note, numerical differences in baseline characteristics between the trilaciclib and non-trilaciclib cohorts may impact the outcomes. However, most of the differences were small or biased against the trilaciclib cohort (e.g., a higher percentage of baseline myelosuppressive HAE rates). Although the follow-up time was generally shorter in the trilaciclib cohorts, the duration of chemotherapy exposure was comparable between the trilaciclib and non-trilaciclib cohorts on the basis of the data from the iKM-based study. Given that myelosuppressive HAEs are related to the duration of chemotherapy exposure, we do not expect the difference in the follow-up time would bias the results. Overall, the outcomes are generally consistent across individual studies though there were some variations in prevalence rates between studies. Such variations may be related to the criteria with which trilaciclib patients were selected, certain baseline differences, and some unobserved factors. For example, the iKM non-network and the FCS trilaciclib studies had higher rates of grade ≥ 3 myelosuppressive HAEs at baseline than the iKM network trilaciclib study, and some rates were much higher than the corresponding historical non-trilaciclib cohorts [
34,
35].
Mirroring the myelosuppressive HAE outcomes, real-world studies also showed generally lower cytopenia-related healthcare utilization in trilaciclib-treated patients than the corresponding historical non-trilaciclib cohorts [
34,
35]. The reduced utilization was more prominent in G-CSF, particularly its use within 3 days after the index date, which was used as a proxy of prophylactic G-CSF use. Evidence on other outcomes is extremely limited in the real world. Two studies evaluated dose reduction and treatment delay and the results suggest the potential impact of trilaciclib on reducing these outcomes [
14,
34]. Only one study reported hospitalization [
37], which indicated that trilaciclib may be associated with lower hospitalization rate and shorter LOS.
In addition, results for the subgroup of LOT1 trilaciclib initiators generally showed numerically lower prevalence of grade ≥ 3 myelosuppressive HAEs, cytopenia-related healthcare utilization, and rates of dose reduction and treatment delay than the overall trilaciclib cohorts [
39,
40]. The differences are more pronounced in grade 4 myelosuppressive HAEs, G-CSF use within 3 days after the index date, and ESA use. Moreover, none of the LOT1 trilaciclib initiators were considered platelet transfusion eligible. These findings suggest potentially greater benefits if trilaciclib is administered before the initiation of the first-line therapy.
Despite the differences in certain patient characteristics between trilaciclib real-world studies and clinical trials, results from both types of studies suggest that trilaciclib is associated with lower grade ≥ 3 myelosuppressive HAE rates and lower cytopenia-related resource utilization. The weighted average prevalence of any grade ≥ 3 myelosuppressive HAE, grade ≥ 3 neutropenia, grade ≥ 3 anemia and grade ≥ 3 thrombocytopenia in the trilaciclib cohorts was 40.5%, 29.1%, 18.3%, and 17.6%, respectively, similar to the corresponding rates in the pooled analysis of clinical trials, i.e., 44.3%, 32.0%, 16.4%, and 18.0%, respectively [
28]. The weighted average prevalences of grade ≥ 3 neutropenia + grade ≥ 3 thrombocytopenia and grade ≥ 3 myelosuppressive HAEs in all three lineages in real-world studies were also within the ranges reported from individual trials [
28]. Rates of cytopenia-related healthcare utilization are not directly comparable between the trilaciclib real-world studies and clinical trials because of variations in treatment protocols and outcomes definitions. For example, the rates of RBC and platelet transfusions were based on the observed outcomes in clinical trials but proxies in some real-world studies. Despite the differences, both real-world studies and clinical trials reported lower rates of G-CSF use and RBC transfusion in trilaciclib-treated patients [
27]. The findings are less consistent in ESA use and platelet transfusion. The clinical trials found a significantly lower rate of ESA use in the trilaciclib arm but a similar rate of platelet transfusion between trilaciclib and placebo. In contrast, real-world studies showed a similar rate of ESA use but a lower rate of platelet transfusion/transfusion eligible between the trilaciclib cohort and the historical non-trilaciclib group in the pooled analysis. Regarding dose reduction, treatment delay and HCRU, real-world evidence is limited. However, the existing evidence suggests lower rates of dose reduction and treatment delay, a lower rate of hospitalization, and shorter LOS in trilaciclib-treated patients compared to the historical non-trilaciclib cohorts, similar to the findings in the clinical trials [
23‐
26].
The current real-world evidence on trilaciclib should be interpreted in the context of the limitations of existing studies, with the most important ones being lack of comparative effectiveness studies and small sample size. Of all three identified real-world trilaciclib studies, two were single-arm studies with only trilaciclib-treated patients [
34,
35]. Even though the Integra Connect study reported outcomes of both trilaciclib- and non-trilaciclib-treated patients [
37], it did not perform a formal comparison between the two groups possibly because of the small sample size of trilaciclib-treated patients (
n = 21). Small sample size is a common limitation in all trilaciclib studies, which is not surprising as a result of the recent approval of trilaciclib. These limitations pointed out important gaps in the real-world evidence on trilaciclib, which can be potentially addressed by future studies. Comparative effectiveness studies with a comparable non-trilaciclib cohort and adjustment for confounding factors will provide more robust evidence on the real-world effectiveness of trilaciclib and should be included in the agenda for future studies. In addition, it is also recommended to increase the sample size in future studies and further evaluate the outcomes in subgroups. Moreover, with a larger sample size and longer follow-up time, future real-world studies may include additional outcomes, such as progression-free survival and overall survival as well as safety outcomes.
The current literature review provides timely real-world evidence on trilaciclib to support treatment decision-making. To comprehensively synthesize the existing evidence, great effort was devoted to identifying the studies that are not in the public domain. In addition, to facilitate the interpretation of the results for trilaciclib-treated patients, comparable non-trilaciclib cohorts were also identified and summarized in the current review. The findings support the benefits of trilaciclib that have been demonstrated in the clinical trials. The effect of trilaciclib on reducing grade ≥ 3 myelosuppressive HAEs as well as dose reduction and treatment delay may potentially translate into better clinical outcomes and QoL among patients with ES-SCLC. Trilaciclib may be particularly beneficial to patients who suffer from myelosuppressive HAEs in all three lineages. Moreover, potential reduction in cytopenia-related healthcare utilization and hospitalizations may alleviate overall burden of ES-SCLC on healthcare systems. The impact of trilaciclib on ES-SCLC management may be even greater in the context of the COVID-19 pandemic. Patients with cancer are at higher risk than those without cancer of being infected with COVID-19 and suffering from serious complications [
41]. In addition, COVID-19 has exacerbated constraints in healthcare resources [
41]. Reduction in blood donation due to social isolation and fear of COVID-19 infection has led to limited blood supplies for patients with severe myelosuppressive HAEs who need transfusion. Concerns over hospitalization may direct physicians to use “safer” cancer treatments that are less effective. Trilaciclib may reduce patients’ susceptibility to viral infection and alleviate the concerns over limited resources by reducing the need for blood transfusions and hospitalization related to CIM in patients with ES-SCLC.